-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36

Benzinga·08/11/2026 17:52:41
Listen to the news
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.